Abstract:Background Invasive fungal infection (IFI) is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of pathogens determination and illness of the hosts. The aim of this study was to evaluate the efficacy and safety of itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematologic malignancies.Methods Two hundred and seventy-four patients with hematologic malignancies who had suspected fungal infections were enrolled in 18 centers across China between April 2008 and April 2009. Empirical antifungal therapy with intravenous itraconazole 200 mg twice daily was given for the first two days, followed by 200 mg once daily for the next 12 days. Oral itraconazole solution was sequential for follow-up therapy if necessary. Five composite end points were evaluated for the response, which was more restrictive and adopted for the first time in such study in China.Results The intent-to-treat analysis included data from 274 patients (full analysis set, FAS), of whom 248 were included as the per-protocol population (PPS). As the composite end point of five indices was concerned, the overall response rate was 43.4%. Seperately, defervescence was achieved in 90% of patients in which 55.5% occured during neutropenia. The mean time to defervescence was 2.71 days. Absence of breakthrough IFI during drug administration or within the first 7 days after study completion was observed in 71.5% of patients. Fifty-five point five percent patients with IFI at baseline was successfully treated. Ninety point five percent patients survived for at least 7 days after completing the study. PPS analysis revealed that the duration of neutropenia >= 10 days was a statistically significant negative predictor for the response. The withdrawal rate due to drug-related toxicity or lack of efficacy was 11.0%. The incidence of adverse events was 22.6%, in which 11.6% was study drug related. The most frequent adverse events were mild to moderate liver toxicity.Conclusion ltraconazole shows desirable efficacy and safety as empirical antifungal therapy for febrile neutropenic patients with hematologic malignancies. Chin Med J 2011;124(22):3670-3675

Value of Serum Galactomannan Enzyme Immunoassay Combine with 1, 3 Beta-Glucan Assay for Diagnosis of Invasive Fungal Infection in Hematological Disorders

��清半乳甘露聚糖和血浆（1，3）β—d-葡聚糖检测诊断侵袭性真菌感染

The Diagnostic Efficiency Evaluation of Combination Tuberculosis Interferon-Gamma Release Assay with Human Leukocyte Antigen-G for Tuberculosis

The diagnostic value of detecting plasma 1,3-β-D-glucan for invasive fungal infections

Diagnostic Value of (1,3)-Β-d-glucan Assay and Galactomannan Test for Invasive Fungal Infection in Patients of Acute Radiation Sickness

Diagnostic value of Chinese assay of (1,3)-β-D-glucan in invasive fungal infections

[Investigation of the Cutoff Value of a Serum 1,3-Beta-d-glucan Assay for Early Diagnosis of Invasive Fungal Infection in Chinese Hematopoietic Stem Cell Transplant Recipients].

[The Value of Serum Galactomannan Detection for Diagnosis of Invasive Aspergillosis in Hematopoietic Stem Cell Transplant Recipients].

Detection Of Galactomannan And (1-3)-Beta-D-Glucan For Early Diagnosis Of Invasive Aspergillosis In Hematological Cancer Patients

Six-year experience with GM test in hematological patients in a public Brazilian tertiary hospital

Diagnostic performance of the (1-3)-β-d-glucan assay in patients with different risks for invasive fungal diseases

[Evaluation of the Galactomannan Assay for the Diagnosis of Invasive Aspergillosis in Patients].

Efficacy and Safety of Itraconazole on Invasive Fungal Infections in 66 Patients with Malignant Hematological Diseases

Positive results of serum galactomannan assays and pulmonary computed tomography predict the higher response rate of empirical antifungal therapy in patients undergoing allogeneic hematopoietic stem cell transplantation.

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

[Combination of Real-Time Polymerase Chain Reaction Assay and Serum Galactomannan in the Diagnosis of Invasive Aspergillosis in Patients with Hematological Malignancies and Recipients of Hematopoietic Stem Cell Transplantation].

Clinical evaluation of two different (1,3)-ß-d-glucan assays for diagnosis of invasive fungal diseases: A retrospective cohort study

A Novel Diagnostic Method for Invasive Fungal Disease Using the Factor G Alpha Subunit From Limulus polyphemus

[Serum Antigens Assay Combined with Chest CT Scan in Diagnosis of Invasive Pulmonary Aspergillosis].

Diagnostic performance of serum galactomannan and β-D-glucan for invasive aspergillosis in suspected patients: A meta-analysis

Value of 1-3-β-D glucan in diagnosis of AIDS-related Pneumocystis pneumonia